<Table 1>
 <caption text="

   Antibodies to A
   
    β
   
   currently in clinical development.
  
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="Antibody">
  </cell>
  <cell col="1" row="0" text="Epitope location">
  </cell>
  <cell col="2" row="0" text="Immunization strategy">
  </cell>
  <cell col="3" row="0" text="Binding Selectivity">
  </cell>
  <cell col="4" row="0" text="Ab species and backbone isotype">
  </cell>
  <cell col="5" row="0" text="Current Status (2019-2020)">
  </cell>
  <cell col="6" row="0" text="Company">
  </cell>
  <cell col="7" row="0" text="Clinical outcomes">
  </cell>
 </row>
 <row row="1">
  <cell col="7" row="1" text="Last completed Trial (Phase)">
  </cell>
  <cell col="8" row="1" text="Patient stage">
  </cell>
  <cell col="9" row="1" text="Reduced brain Ab burden">
  </cell>
  <cell col="10" row="1" text="Slowing of cognitive decline">
  </cell>
  <cell col="11" row="1" text="ARIA-E or ARIA-H">
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="Bapineuzumab (AAB-001, 3D6)">
  </cell>
  <cell col="1" row="2" text="1–5">
  </cell>
  <cell col="2" row="2" text="A
     
      β
     
     (1–5) conjugated to immunoglobulin">
  </cell>
  <cell col="3" row="2" text="M,O,F/P">
  </cell>
  <cell col="4" row="2" text="Humanized IgG1">
  </cell>
  <cell col="5" row="2" text="NCT00998764
     
     ,
     
      NCT00667810
     
     ,
     
      NCT00996918
     
     (III,D)">
  </cell>
  <cell col="6" row="2" text="Janssen/Pfizer">
  </cell>
  <cell col="7" row="2" text="NCT00575055
     
     ,
     
      NCT00574132
     
     (III)">
  </cell>
  <cell col="8" row="2" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="2" text="+">
  </cell>
  <cell col="10" row="2" text="−">
  </cell>
  <cell col="11" row="2" text="high">
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="Solanezumab (LY2062430, m266)">
  </cell>
  <cell col="1" row="3" text="16–26">
  </cell>
  <cell col="2" row="3" text="A
     
      β
     
     peptide 13–28">
  </cell>
  <cell col="3" row="3" text="M++,O,F/P-">
  </cell>
  <cell col="4" row="3" text="Humanized IgG1">
  </cell>
  <cell col="5" row="3" text="NCT01900665
     
     (III,halted),
     
      NCT02008357
     
     (III)">
  </cell>
  <cell col="6" row="3" text="Eli Lilly">
  </cell>
  <cell col="7" row="3" text="NCT00904683
     
     ,
     
      NCT00905372
     
     (III)">
  </cell>
  <cell col="8" row="3" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="3" text="+">
  </cell>
  <cell col="10" row="3" text="+/−§">
  </cell>
  <cell col="11" row="3" text="no">
  </cell>
 </row>
 <row row="4">
  <cell col="0" row="4" text="Ponezumab (PF-04360365)">
  </cell>
  <cell col="1" row="4" text="30–40">
  </cell>
  <cell col="2" row="4" text="A
     
      β
     

      40
     
     40">
  </cell>
  <cell col="3" row="4" text="M+,O,F (A
     
      β
     

      40
     
     40)">
  </cell>
  <cell col="4" row="4" text="Humanized IgG2a">
  </cell>
  <cell col="5" row="4" text="NCT00945672
     
     (II,D)">
  </cell>
  <cell col="6" row="4" text="Janssen/Pfizer">
  </cell>
  <cell col="7" row="4" text="NCT00722046
     
     (II)">
  </cell>
  <cell col="8" row="4" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="4" text="−">
  </cell>
  <cell col="10" row="4" text="−">
  </cell>
  <cell col="11" row="4" text="low ARIA-H, low ARIA-E">
  </cell>
 </row>
 <row row="5">
  <cell col="0" row="5" text="Crenezumab (MABT5102A, RG7412)">
  </cell>
  <cell col="1" row="5" text="13–24">
  </cell>
  <cell col="2" row="5" text="liposome-anchored peptides">
  </cell>
  <cell col="3" row="5" text="M-,O, F/P">
  </cell>
  <cell col="4" row="5" text="Humanized IgG4">
  </cell>
  <cell col="5" row="5" text="NCT02670083
     
     (III,D),
     
      NCT01998841
     
     (II)">
  </cell>
  <cell col="6" row="5" text="Roche/Genentech">
  </cell>
  <cell col="7" row="5" text="NCT01723826
     
     (II)">
  </cell>
  <cell col="8" row="5" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="5" text="−">
  </cell>
  <cell col="10" row="5" text="−">
  </cell>
  <cell col="11" row="5" text="low">
  </cell>
 </row>
 <row row="6">
  <cell col="0" row="6" text="Gantenerumab (RO4909832, RG1450)">
  </cell>
  <cell col="1" row="6" text="2–11 and 18–27">
  </cell>
  <cell col="2" row="6" text="N/A: human combinatorial antibody libraries">
  </cell>
  <cell col="3" row="6" text="M-, O, F/P+">
  </cell>
  <cell col="4" row="6" text="human IgG1">
  </cell>
  <cell col="5" row="6" text="NCT03443973
     
     ,
     
      NCT03444870
     
     (III)">
  </cell>
  <cell col="6" row="6" text="Hoffman-La Roche">
  </cell>
  <cell col="7" row="6" text="NCT01224106
     
     ,
     
      NCT02051608
     
     (III)">
  </cell>
  <cell col="8" row="6" text="Prodromal to mild AD">
  </cell>
  <cell col="9" row="6" text="+">
  </cell>
  <cell col="10" row="6" text="−">
  </cell>
  <cell col="11" row="6" text="high: 2/6 patients (200 mg dose)">
  </cell>
 </row>
 <row row="7">
  <cell col="0" row="7" text="Donanemab (N3pG, LY-3002813, mE8)">
  </cell>
  <cell col="1" row="7" text="p3–7">
  </cell>
  <cell col="2" row="7" text="A
     
      β
     
     pE3–42 peptide">
  </cell>
  <cell col="3" row="7" text="F/P (N3pG)">
  </cell>
  <cell col="4" row="7" text="Humanized IgG1">
  </cell>
  <cell col="5" row="7" text="NCT02624778
     
     (I),
     
      NCT03367403
     
     (II)">
  </cell>
  <cell col="6" row="7" text="Eli Lilly">
  </cell>
  <cell col="7" row="7" text="NCT01837641
     
     (I)">
  </cell>
  <cell col="8" row="7" text="Early/mild AD">
  </cell>
  <cell col="9" row="7" text="+">
  </cell>
  <cell col="10" row="7" text="n/a">
  </cell>
  <cell col="11" row="7" text="moderate; immunogenic">
  </cell>
 </row>
 <row row="8">
  <cell col="0" row="8" text="Aducanumab (BIIB037)">
  </cell>
  <cell col="1" row="8" text="3–7">
  </cell>
  <cell col="2" row="8" text="N/A: B-cell libraries from healthy elderly subjects">
  </cell>
  <cell col="3" row="8" text="M-,O,F/P">
  </cell>
  <cell col="4" row="8" text="Human IgG1">
  </cell>
  <cell col="5" row="8" text="NCT02477800
     
     ,
     
      NCT02484547
     
     (III, D)">
  </cell>
  <cell col="6" row="8" text="Neurimmune/Eisai/Biogen">
  </cell>
  <cell col="7" row="8" text="NCT02477800
     
     ,
     
      NCT02484547
     
     (III)">
  </cell>
  <cell col="8" row="8" text="Early AD">
  </cell>
  <cell col="9" row="8" text="+">
  </cell>
  <cell col="10" row="8" text="−">
  </cell>
  <cell col="11" row="8" text="high">
  </cell>
 </row>
 <row row="9">
  <cell col="0" row="9" text="SAR-228810 (SAR255952, 13C3)">
  </cell>
  <cell col="1" row="9" text="N-terminus (4–20)">
  </cell>
  <cell col="2" row="9" text="Synthetic oligomers">
  </cell>
  <cell col="3" row="9" text="O,F/P">
  </cell>
  <cell col="4" row="9" text="Humanized IgG4">
  </cell>
  <cell col="5" row="9" text="NCT01485302
     
     (I)">
  </cell>
  <cell col="6" row="9" text="Sanofi">
  </cell>
  <cell col="7" row="9" text="NCT01485302
     
     (I)">
  </cell>
  <cell col="8" row="9" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="9" text="n/a">
  </cell>
  <cell col="10" row="9" text="n/a">
  </cell>
  <cell col="11" row="9" text="no ARIA-E, very low ARIA-H">
  </cell>
 </row>
 <row row="10">
  <cell col="0" row="10" text="BAN-2401 (Lecanemab, mAb158)">
  </cell>
  <cell col="1" row="10" text="N-terminus (1–16)">
  </cell>
  <cell col="2" row="10" text="Protofibrils of E22G mutant A
     
      β">
  </cell>
  <cell col="3" row="10" text="M-,O+, F/P">
  </cell>
  <cell col="4" row="10" text="Humanized IgG1">
  </cell>
  <cell col="5" row="10" text="NCT03887455
     
     (III)">
  </cell>
  <cell col="6" row="10" text="Biogen/Eisai/BioArctic">
  </cell>
  <cell col="7" row="10" text="NCT01230853
     
     (I), (Iib)">
  </cell>
  <cell col="8" row="10" text="Mild to moderate AD/Early AD">
  </cell>
  <cell col="9" row="10" text="+">
  </cell>
  <cell col="10" row="10" text="+/−">
  </cell>
  <cell col="11" row="10" text="low">
  </cell>
 </row>
 <row row="11">
  <cell col="0" row="11" text="MEDI-1814">
  </cell>
  <cell col="1" row="11" text="A
     
      β
     

      42
     
     2C-terminus (29–42)">
  </cell>
  <cell col="2" row="11" text="N/A: human combinatorial antibody libraries">
  </cell>
  <cell col="3" row="11" text="M++,O">
  </cell>
  <cell col="4" row="11" text="Human IgG1">
  </cell>
  <cell col="5" row="11" text="NCT02036645
     
     (I)">
  </cell>
  <cell col="6" row="11" text="Eli Lilly/AstraZeneca/MedImmune">
  </cell>
  <cell col="7" row="11" text="NCT02036645
     
     (I)">
  </cell>
  <cell col="8" row="11" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="11" text="n/a">
  </cell>
  <cell col="10" row="11" text="n/a">
  </cell>
  <cell col="11" row="11" text="no">
  </cell>
 </row>
 <row row="12">
  <cell col="0" row="12" text="KHK6640">
  </cell>
  <cell col="1" row="12" text="Not known/Not disclosed">
  </cell>
  <cell col="2" row="12" text="Not available">
  </cell>
  <cell col="3" row="12" text="O,F/P">
  </cell>
  <cell col="4" row="12" text="Humanized IgG4">
  </cell>
  <cell col="5" row="12" text="NCT03093519
     
     (I)">
  </cell>
  <cell col="6" row="12" text="Kyowa Hakko Kirin">
  </cell>
  <cell col="7" row="12" text="NCT02127476
     
     (I),
     
      NCT03093519
     
     (I)">
  </cell>
  <cell col="8" row="12" text="Prodromal/Mild/Moderate AD">
  </cell>
  <cell col="9" row="12" text="n/a">
  </cell>
  <cell col="10" row="12" text="−">
  </cell>
  <cell col="11" row="12" text="no ARIA-E, moderate ARIA-H">
  </cell>
 </row>
 <row row="13">
  <cell col="0" row="13" text="Plasma Exchange/Albumen replacement, IVIgs">
  </cell>
  <cell col="1" row="13" text="n/a">
  </cell>
  <cell col="2" row="13" text="Serum of multiple healthy young volunteers">
  </cell>
  <cell col="3" row="13" text="M,O,F/P">
  </cell>
  <cell col="4" row="13" text="n/a">
  </cell>
  <cell col="5" row="13" text="NCT01561053
     
     (II/III)">
  </cell>
  <cell col="6" row="13" text="Grifols Biologicals Inc.">
  </cell>
  <cell col="7" row="13" text="NCT00818662
     
     (III)">
  </cell>
  <cell col="8" row="13" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="13" text="+/−">
  </cell>
  <cell col="10" row="13" text="−">
  </cell>
  <cell col="11" row="13" text="none">
  </cell>
 </row>
 <row row="14">
  <cell col="0" row="14" text="NPT088">
  </cell>
  <cell col="1" row="14" text="noncontiguous −12, 17–25, and 31–40">
  </cell>
  <cell col="2" row="14" text="N/A: Human IgG -viral g3p GAIM chimera">
  </cell>
  <cell col="3" row="14" text="O,F/P">
  </cell>
  <cell col="4" row="14" text="Human IgG1">
  </cell>
  <cell col="5" row="14" text="NCT03008161
     
     (I)">
  </cell>
  <cell col="6" row="14" text="Proclara Biosciences">
  </cell>
  <cell col="7" row="14" text="NCT03008161
     
     (I)">
  </cell>
  <cell col="8" row="14" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="14" text="n/a">
  </cell>
  <cell col="10" row="14" text="n/a">
  </cell>
  <cell col="11" row="14" text="−">
  </cell>
 </row>
 <statements>
  <statement id="0" text="There are 13 unique antibody ." type="">
  </statement>
  <statement id="1" text="Epitope location is having unique values." type="">
  </statement>
  <statement id="3" text="There are unique Company's observed." type="">
  </statement>
  <statement id="4" text="Reduced brain Ab burden is having + and - in the studies." type="">
  </statement>
  <statement id="5" text="Slowing of cognitive decline is also having + and - in the studies." type="">
  </statement>
 </statements>
</Table 1>
<Table 2>
 <caption text="

   Antibodies to tau currently in clinical development.
  
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="Antibody">
  </cell>
  <cell col="1" row="0" text="Epitope location">
  </cell>
  <cell col="2" row="0" text="Immunization strategy">
  </cell>
  <cell col="3" row="0" text="Binding Selectivity">
  </cell>
  <cell col="4" row="0" text="Ab species and backbone isotype">
  </cell>
  <cell col="5" row="0" text="Current Status (2019–2020)">
  </cell>
  <cell col="6" row="0" text="Company">
  </cell>
  <cell col="7" row="0" text="Clinical outcomes">
  </cell>
 </row>
 <row row="1">
  <cell col="7" row="1" text="Last completed Trial (Disease,Phase)">
  </cell>
  <cell col="8" row="1" text="Patient stage">
  </cell>
  <cell col="9" row="1" text="Reduced tau burden">
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="Gosuranemab, BIIB092, BMS-986168, IPN007/IPN002)">
  </cell>
  <cell col="1" row="2" text="15–24">
  </cell>
  <cell col="2" row="2" text="In vitro aggregated full-length tau">
  </cell>
  <cell col="3" row="2" text="M, NFT?, eTau">
  </cell>
  <cell col="4" row="2" text="humanized IgG4">
  </cell>
  <cell col="5" row="2" text="NCT03352557
     
     (AD,II)">
  </cell>
  <cell col="6" row="2" text="iPerian/Bristol-Meyers Squibb/Biogen">
  </cell>
  <cell col="7" row="2" text="NCT02460094
     
     (PSP,I),
     
      NCT03068468
     
     (PSP,II,d
     )">
  </cell>
  <cell col="8" row="2" text="MCI/Mild AD">
  </cell>
  <cell col="9" row="2" text="+">
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="ABBV-8E12 (C2N-8E12, HJ8.5)">
  </cell>
  <cell col="1" row="3" text="25–30 (within 22–34)">
  </cell>
  <cell col="2" row="3" text="recombinant full-length tau">
  </cell>
  <cell col="3" row="3" text="M, NFT, eTau">
  </cell>
  <cell col="4" row="3" text="humanized IgG4">
  </cell>
  <cell col="5" row="3" text="NCT03712787
     
     (AD,II),
     
      NCT02880956
     
     (AD,II)">
  </cell>
  <cell col="6" row="3" text="C2N Diagnostics/Abbvie">
  </cell>
  <cell col="7" row="3" text="NCT02494024
     
     (PSP,I)
     
      NCT03391765
     
     (PSP,I,d)">
  </cell>
  <cell col="8" row="3" text="Early AD">
  </cell>
  <cell col="9" row="3" text="+">
  </cell>
 </row>
 <row row="4">
  <cell col="0" row="4" text="Zagotenemab (LY3303560, MC-1 IgG1)">
  </cell>
  <cell col="1" row="4" text="7–9/312–322 (discontiguous)">
  </cell>
  <cell col="2" row="4" text="Immunopurified PHFs">
  </cell>
  <cell col="3" row="4" text="M-,O,NFT">
  </cell>
  <cell col="4" row="4" text="humanized IgG4">
  </cell>
  <cell col="5" row="4" text="NCT03518073
     
     (AD,II)">
  </cell>
  <cell col="6" row="4" text="Eli Lilly">
  </cell>
  <cell col="7" row="4" text="NCT02754830
     
     ,
     
      NCT03019536
     
     (AD,I)">
  </cell>
  <cell col="8" row="4" text="healthy, mild to moderate AD">
  </cell>
  <cell col="9" row="4" text="–">
  </cell>
 </row>
 <row row="5">
  <cell col="0" row="5" text="Semorinemab (RO7105705, MTAU9937A, RG6100)">
  </cell>
  <cell col="1" row="5" text="2–24 (C-terminal portion)">
  </cell>
  <cell col="2" row="5" text="recombinant oligomers">
  </cell>
  <cell col="3" row="5" text="M,NFT,eTau">
  </cell>
  <cell col="4" row="5" text="humanized IgG4">
  </cell>
  <cell col="5" row="5" text="NCT03828747
     
     (AD,II),
     
      NCT03289143
     
     (AD,II)">
  </cell>
  <cell col="6" row="5" text="AC Immune, Genentech, Hoffmann-La Roche">
  </cell>
  <cell col="7" row="5" text="NCT02820896
     
     (AD,I)">
  </cell>
  <cell col="8" row="5" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="5" text="+">
  </cell>
 </row>
 <row row="6">
  <cell col="0" row="6" text="BIIB076 (NI-105.6C5 huIgG1
     
      λ
     
     )">
  </cell>
  <cell col="1" row="6" text="probably −131">
  </cell>
  <cell col="2" row="6" text="N/A: B-cells from healthy subjects">
  </cell>
  <cell col="3" row="6" text="M, PFF, NFT">
  </cell>
  <cell col="4" row="6" text="human IgG1">
  </cell>
  <cell col="5" row="6" text="NCT03056729
     
     (AD,I)">
  </cell>
  <cell col="6" row="6" text="Biogen/Neurimmune">
  </cell>
  <cell col="7" row="6" text="NCT03056729
     
     (AD,I)">
  </cell>
  <cell col="8" row="6" text="Healthy/MCI AD">
  </cell>
  <cell col="9" row="6" text="+">
  </cell>
 </row>
 <row row="7">
  <cell col="0" row="7" text="RG7345 (RO6926496)">
  </cell>
  <cell col="1" row="7" text="416–430 (pS422)">
  </cell>
  <cell col="2" row="7" text="416–430 (pS422) peptide">
  </cell>
  <cell col="3" row="7" text="phospho M, PHF">
  </cell>
  <cell col="4" row="7" text="humanized IgG1 or IgG4">
  </cell>
  <cell col="5" row="7" text="NCT02281786
     
     (I,d)">
  </cell>
  <cell col="6" row="7" text="Hoffmann-La Roche">
  </cell>
  <cell col="7" row="7" text="NCT02281786
     
     (I,d)">
  </cell>
  <cell col="8" row="7" text="healthy males">
  </cell>
  <cell col="9" row="7" text="−">
  </cell>
 </row>
 <row row="8">
  <cell col="0" row="8" text="UCB0107 (D IgG4)">
  </cell>
  <cell col="1" row="8" text="235–246">
  </cell>
  <cell col="2" row="8" text="Recombinant tau fibrils">
  </cell>
  <cell col="3" row="8" text="M,O,PHF">
  </cell>
  <cell col="4" row="8" text="humanized IgG4 or IgG1">
  </cell>
  <cell col="5" row="8" text="NCT03464227
     
     (AD,I),
     
      NCT03605082
     
     (AD,I)
     
      NCT04185415
     
     (PSP,I,s)">
  </cell>
  <cell col="6" row="8" text="UCB Biopharma">
  </cell>
  <cell col="7" row="8" text="NCT03464227
     
     (I),
     
      NCT03605082
     
     (I)">
  </cell>
  <cell col="8" row="8" text="Healthy males, healthy m/f">
  </cell>
  <cell col="9" row="8" text="−">
  </cell>
 </row>
 <row row="9">
  <cell col="0" row="9" text="JNJ-63733657 (B296, PT3)">
  </cell>
  <cell col="1" row="9" text="204–225 (pT212/pT217)">
  </cell>
  <cell col="2" row="9" text="PHF from AD patients">
  </cell>
  <cell col="3" row="9" text="M,PHF (ptau)">
  </cell>
  <cell col="4" row="9" text="humanized, likely IgG1">
  </cell>
  <cell col="5" row="9" text="NCT03375697
     
     (prodromal, mild AD,I)">
  </cell>
  <cell col="6" row="9" text="Janssen">
  </cell>
  <cell col="7" row="9" text="NCT03689153
     
     (I)">
  </cell>
  <cell col="8" row="9" text="healthy m/f">
  </cell>
  <cell col="9" row="9" text="+">
  </cell>
 </row>
 <row row="10">
  <cell col="0" row="10" text="NPT088">
  </cell>
  <cell col="1" row="10" text="noncontiguous 11–12, 17–25 and 31–40">
  </cell>
  <cell col="2" row="10" text="N/A: Human IgG -viral g3p GAIM chimera">
  </cell>
  <cell col="3" row="10" text="O,F/P">
  </cell>
  <cell col="4" row="10" text="Human IgG1">
  </cell>
  <cell col="5" row="10" text="NCT03008161
     
     (I)">
  </cell>
  <cell col="6" row="10" text="Proclara Biosciences">
  </cell>
  <cell col="7" row="10" text="NCT03008161
     
     (I)">
  </cell>
  <cell col="8" row="10" text="Mild to moderate AD">
  </cell>
  <cell col="9" row="10" text="−">
  </cell>
 </row>
 <statements>
  <statement id="4" text="The clinical outcomes are observed to be unique according to patients." type="">
  </statement>
  <statement id="5" text="These results established a positive safety profile for inclusion of BIIB076 into phase I trials." type="">
  </statement>
  <statement id="6" text="This trial ( NCT03056729 ) recruited healthy and mild-AD volunteers to monitor adverse events and pharmacokinetics ( Table 2 )." type="">
  </statement>
 </statements>
</Table 2>